Prevent the Preventable

Every year millions of people are affected by postoperative respiratory complications. In US alone, more than 100’000 patients annually are at risk of adverse events associated with undetected residual neuromuscular blockade.

Senzime´s innovative device, TetraGraph, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBA´s).

TetraGraph can be used from start to finish during the surgical procedure and it enables objective assessment of  correct dose of medication and helps to determine when the patient is recovered sufficiently to cope with vital spontaneous breathing.

Senzime, Inc. is headquartered in Naples, Florida.

Residual Neuromuscular Blockade

Qualitative vs Quantitative Monitoring

EMG Technology-

New Gold Standard

Press releases

Breakthrough orders for Senzime in the UK

Read more

COVID-19 – Update from Senzime

Read more

Senzime’s Year-End Report 2019

Read more
See all »

News

Senzime secures the first sales in the US market

Read more

Launch of TetraGraph Philips Interface

Read more

New research data proves the value of accurate monitoring of patients after use of muscle relaxants

Read more
See all »